Magazine Article | September 1, 2022

Nonprofit Pursues Oncology Drugs

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Reboot Rx does not aim to rescue undeveloped drugs; it intends to give approved generic drugs a new life in oncology. The company is founded on a well-supported assumption: Many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: